The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.
Study Type
OBSERVATIONAL
Enrollment
264
The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Pfizer Investigational Site
Kayseri, Turkey, Turkey (Türkiye)
Pfizer Investigational Site
Kocaeli, Turkey, Turkey (Türkiye)
Pfizer Investigational Site
Ankara, Turkey (Türkiye)
Pfizer Investigational Site
Bursa, Turkey (Türkiye)
Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach: Empirical
Time frame: Baseline
Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring FEN in Their Therapeutical Approach: Targeted
Time frame: Baseline
Mean Body Temperature
Time frame: Baseline, Day 4, Day 7 on Average (till the End of Treatment)
Mean Neutrophil Count
Time frame: Baseline, Day 4, Day 7 on Average (till the End of Treatment)
Percentage of Participants in Whom New Infection Was Determined on Day 4
Time frame: Day 4
Percentage of Participants in Whom New Infection Was Determined at End of Treatment
Time frame: Day 7 on Average (till the End of Treatment)
Percentage Survivors
Time frame: Day 7 on Average (till the End of Treatment)
Percentage of Participants Who Had a Treatment Modification
Time frame: Day 4, Day 7 on Average (till the End of Treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Istanbul, Turkey (Türkiye)